UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Drug design, development and therapy, 2020-02, Vol.14, p.469-481

Le Quellec, Sandra

2020

Volltextzugriff (PDF)

Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature

Thrombosis and haemostasis, 2016-10, Vol.116 (4), p.638-650

2016

Volltextzugriff (PDF)

Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-01, Vol.30 (1), p.5-15

2024

Volltextzugriff (PDF)

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

Haematologica (Roma), 2018-04, Vol.103 (4), p.e181-e183

2018

Volltextzugriff (PDF)

Septic Arthritis Caused by Noncapsulated Haemophilus influenzae

Journal of Clinical Microbiology, 2013-06, Vol.51 (6), p.1970-1972

2013

Volltextzugriff (PDF)

A 360-degree perspective on adeno-associated virus (AAV)-based gene therapy for haemophilia: Insights from the physician, the nurse and the patient

Orphanet journal of rare diseases, 2024-05, Vol.19 (1), p.193-193, Article 193

2024

Volltextzugriff (PDF)

Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single‐centre study

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-03, Vol.28 (2), p.301-307

2022

Volltextzugriff (PDF)

Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-03, Vol.28 (2), p.215-222

2022

Volltextzugriff (PDF)

FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review

International journal of molecular sciences, 2021-06, Vol.22 (12), p.6475

2021

Volltextzugriff (PDF)

Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.e487-e490

2021

Volltextzugriff (PDF)

A single‐centre study of management of pregnant women with von Willebrand disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-01, Vol.25 (1), p.e54-e57

2019

Volltextzugriff (PDF)

Potential limits of AAV‐based gene therapy with the use of new transgenes expressing factor IX fusion proteins

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-01, Vol.25 (1), p.e11-e18

2019

Volltextzugriff (PDF)

Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice

Thrombosis and haemostasis, 2019-12, Vol.119 (12), p.1956-1967

2019

Volltextzugriff (PDF)

Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays

Thrombosis research, 2017-05, Vol.153, p.7-13

2017

Volltextzugriff (PDF)

Single‐center determination of reference factor II and factor X activity level values for the monitoring of vitamin K antagonist therapy

International journal of laboratory hematology, 2019-10, Vol.41 (5), p.e121-e123

2019

Volltextzugriff (PDF)

Le choix du concentré de facteur VIII recombinant influence-t-il le développement d’inhibiteurs chez les patients hémophiles A ?

Hématologie, 2015-01, Vol.21 (1), p.12-14

Le Quellec, Sandra

2015

Volltextzugriff (PDF)

The potential value of thrombin generation assay in the diagnosis of FV inhibitors

International journal of laboratory hematology, 2019-10, Vol.41 (5), p.e117-e120

2019

Volltextzugriff (PDF)

Intérêt de la protéine de fusion recombinante facteur VIII-Fc chez les patients hémophiles A sévères

Hématologie, 2014-11, Vol.20 (6), p.304-306

Le Quellec, Sandra

2014

Volltextzugriff (PDF)

Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?

PloS one, 2017-11, Vol.12 (11), p.e0188213-e0188213

2017

Volltextzugriff (PDF)

Discrepancies in FVII:C levels depending on the thromboplastin: about a case

Annales de biologie clinique (Paris), 2020-04, Vol.78 (2), p.198-200

2020

Volltextzugriff (PDF)

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

The Lancet. Haematology, 2024-04, Vol.11 (4), p.e265-e275

2024

Volltextzugriff (PDF)

Differential diagnosis of neonatal alloimmune thrombocytopenia: Type 2B von Willebrand disease

Platelets (Edinburgh), 2017-12, Vol.28 (8), p.825-828

2017

Volltextzugriff (PDF)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

Research and practice in thrombosis and haemostasis, 2022-05, Vol.6 (4), p.e12731-n/a, Article e12731

2022

Volltextzugriff (PDF)

Emicizumab should be prescribed independent of immune tolerance induction

Blood advances, 2018-10, Vol.2 (20), p.2783-2786

2018

Volltextzugriff (PDF)

In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study

Journal of thrombosis and haemostasis, 2023-11, Vol.21 (11), p.3117-3123

2023

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(42)
Berichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature

Gene therapy for haemophilia A and B, from basic principles to clinical implementation: An illustrated review

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

Septic Arthritis Caused by Noncapsulated Haemophilus influenzae

A 360-degree perspective on adeno-associated virus (AAV)-based gene therapy for haemophilia: Insights from the physician, the nurse and the patient

Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single‐centre study

Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?

FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review

Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots

A single‐centre study of management of pregnant women with von Willebrand disease

Potential limits of AAV‐based gene therapy with the use of new transgenes expressing factor IX fusion proteins

Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice

Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays

Single‐center determination of reference factor II and factor X activity level values for the monitoring of vitamin K antagonist therapy

Le choix du concentré de facteur VIII recombinant influence-t-il le développement d’inhibiteurs chez les patients hémophiles A ?

The potential value of thrombin generation assay in the diagnosis of FV inhibitors

Intérêt de la protéine de fusion recombinante facteur VIII-Fc chez les patients hémophiles A sévères

Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?

Discrepancies in FVII:C levels depending on the thromboplastin: about a case

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Differential diagnosis of neonatal alloimmune thrombocytopenia: Type 2B von Willebrand disease

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

Emicizumab should be prescribed independent of immune tolerance induction

In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study

Suchergebnisse filtern